Microsatellite instability and hyperplastic processes of the uterine mucosa
https://doi.org/10.31549/2542-1174-2023-7-2-62-76
Abstract
I n t r o d u c t i o n . Microsatellite instability is historically closely associated with the development of oncological processes. Early diagnosis of microsatellite instability as a marker for premalignancy, including in the case of endometrial hyperplasia (EH), which is recognized as a premalignancy lesion, is of interest. Identifi cation of the mutational profile characteristic of malignant tumors in benign disease makes it possible to improve prognostic models and therapeutic tactics.
A i m . Determination of clinical and anamnestic features of patients with EH and endometrioid adenocarcinoma in a comparative aspect, as well as structural features of microsatellite instability in the endometrium in patients with this pathology.
M a t e r i a l s a n d m e t h o d s . The study involved 120 women who were divided into 4 groups: group I – EH patients without atypia (n = 30); group II – patients with atypical EH (n = 30); group III – patients with endometrioid adenocarcinoma (n = 30); group IV – healthy women without somatic and gynecological pathology (n = 30). A comparative morphological study of endometrial samples was performed and levels of MLH-1, MSH-2, MSH-6 and PMS-2 expression were assessed.
R e s u l t s . It was revealed that most EH patients without atypia, patients with atypical EH, endometrioid adenocarcinoma complained of abnormal uterine bleeding; the history of patients of these groups is characterized by the presence of cardiovascular and endocrine diseases, and the gynecological history is characterized by the presence of uterine fibroids, benign breast diseases and pelvic infl ammatory diseases. There was found a decrease in the MLH-1, PMS-2, MSH-2 and MSH-6 expression in endometrial biopsies of women with EH.
C o n c l u s i o n . Decreased expression of MLH-1, PMS-2, MSH-2 and MSH-6 in endometrial biopsies can probably be considered as a predictor of premalignant transformation, which requires further study in order to develop a program of malignancy risk assessment.
About the Authors
E. L. Kazachkov
South Ural State Medical University
Russian Federation
Russian Federation
Evgeny L. Kazachkov – Dr. Sci. (Med.), Professor, Head, V.L. Kovalenko Department of Pathological Anatomy and Forensic Medicine
Chelyabinsk
A. V. Zatvornitskaya
South Ural State Medical University
Russian Federation
Russian Federation
Alexandra V. Zatvornitskaya – Cand. Sci. (Med.), Assistant, V.L. Kovalenko Department of Pathological Anatomy and Forensic Medicine
64, Vorovskogo str., Chelyabinsk, 454092
E. A. Kazachkova
South Ural State Medical University
Russian Federation
Russian Federation
Ella A. Kazachkova – Dr. Sci. (Med.), Professor, Department of Obstetrics and Gynecology
Chelyabinsk
E. E. Voropaeva
South Ural State Medical University
Russian Federation
Russian Federation
Ekaterina E. Voropaeva – Dr. Sci. (Med.), Associate Professor, Professor, V.L. Kovalenko Department of Pathological Anatomy and Forensic Medicine
Chelyabinsk
References
1. Kaprina A.D., Starinsky V.V., Shakhzadova A.O. (eds.) (2021). Malignant Neoplasms in Russia in 2020 (Мorbidity and Мortality). Moscow. 252 p. (In Russ.)
2. Sychevskaya K.A., Erokhina M.V., Kravchenko S.K., Lepekha L.N. Instability of microsatellite repeats in non-tumor lung diseases: association with inflammation. Practical Pulmonology. 2021;1:52-60. (In Russ.)
3. Tryakin A. A., Fedyanin M. Yu., Tsukanov A. S. et al. Microsatellite instability as a unique characteristic of tumors and a predictor of response to immune therapy. Malignant Tumours. 2019;9(4):59-69. DOI: 10.18027/2224-5057-2019-9-4-59-69. (In Russ.)
4. Chang L., Chang M., Chang H.M., Chang F. Microsatellite instability: a predictive biomarker for cancer immunotherapy. Appl. Immunohistochem. Mol. Morphol. 2018;26(2):e15-e21. DOI: 10.1097/PAI.0000000000000575.
5. Deshpande M., Romanski P.A., Rosenwaks Z., Gerhardt J. Gynecological cancers caused by deficient mismatch repair and microsatellite instability. Cancers (Basel). 2020;12(11):3319. DOI: 10.3390/cancers12113319.
6. Musaelyan A.A., Ohanyan K.A., Nazarov V.D. et al. Microsatellite instability in gastric cancer: basic and clinical application. Effective Pharmacotherapy. 2021;17(30):12-17. DOI: 10.33978/2307-3586-2021-17-30-12-17. (In Russ.)
7. Pietrantonio F., Miceli R., Raimondi A. et al. Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J. Clin. Oncol. 2019;37(35):3392-3400. DOI: 10.1200/JCO.19.01124.
8. Cai L., Sun Y., Wang K. et al. The better survival of MSI subtype is associated with the oxidative stress related pathways in gastric cancer. Front. Oncol. 2020;10:1269. DOI: 10.3389/fonc.2020.01269.
9. Martianov A.S., Kuligina E.Sh., Romanko A.A., Imyanitov E.N. Molecular genetic testing in colon cancer: clinical aspects. Almanac of Clinical Medicine. 2022;50(1):1-12. DOI: 10.18786/2072-0505-2022-50-002. (In Russ.)
10. Kit O.I., Gevorkyan Yu.A., Soldatkina N.V. et al. Prognostic factors in colorectal cancer. Koloproktologia. 2021;20(2):42-49. DOI: 10.33878/2073-7556-2021-20-2-42-49. (In Russ.)
11. Lin A., Zhang J., Luo P. Crosstalk between the MSI status and tumor microenvironment in colorectal cancer. Front. Immunol. 2020;11: 20-39. DOI: 10.3389/fimmu.2020.02039.
12. Mastronikolis N., Chrysovergis A., Tsiambas E., Kyrodimos E. Microsatellite instability (MSI) markers in thyroid carcinoma. J. BUON. 2021;26(3):1169.
13. Kuznetsova O.A., Zavalishina L.E., Andreeva Yu.Yu. et al. Immunohistochemical study of MSI markers in breast cancer. Arhiv Patologii. 2021;83(1):12-17. DOI: 10.17116/patol20218301112. (In Russ.)
14. Kazachkov E.L., Voropaeva E.E., Kazachkova E.A. et al. (2019). Pathomorphology of Premalignancies, Tumor-like Lesions and Endometrial Carcinomas. Guideline for Students of the System of Advanced Professional Education in the Specialties “Pathological anatomy” and “Obstetrics and Gynecology.” Chelyabinsk. 127 p. (In Russ.)
15. Lax S.F., Mutter G.L. Endometrial atypical hyperplasia/ endometrioid intraepithelial neoplasia. In I.A. Cree, J. Ferlay, R. Jakob et al. (eds.) (2020). WHO Classifi - cation of Tumours. 5th еd. Female Genital Tumours. IARC Publications. Lyon. P. 250–251.
16. Musaelyan A.A., Nazarov V.D., Budnikova A.S. et al. Clinical and morphological portrait of tumors with microsatellite instability. Advances in Molecular Oncology. 2021;8(2)52-59. DOI: 10.17650/2313-805X-2021-8-2-52-59. (In Russ.)
17. Kondrikov N.I., Barinova I.V. (2019). Pathology of the Uterus. Guide for Doctors. Moscow. 352 p. (In Russ.)
18. Merkulov G.A. (1961). Course of Pathoanatomical Technique. Leningrad. 340 p. (In Russ.)
19. Artemenko Y.S., Khamoshina M.B., Ryabova V.A., Zyukin a Z.V. Obesity in women: current aspects of reproductive health disorders. Meditsinskiy Sovet. 2022;16(5):32-39. DOI: 10.21518/2079-701X-2022-16-5-32-39. (In Russ.)
20. Dubik M.M. Breast cancer risk factors. Scientist. 2022;1(19):19-21. (In Russ.)
21. Orazov M.R., Mikhaleva L.M., Mullina I.A. Endometrial hyperplasia: a modern view of the problem. Obstetrics and Gnecology. News. Opinions. Education. 2022;3(37):62-65. DOI: 10.33029/2303-9698-2022-10-3-62-67. (In Russ.)
22. Iversen M.L., Dueholm M. Complex non atypical hyperplasia and the subsequent risk of carcinoma, atypia and hysterectomy during the following 9–14 years. Eur. J. Obstet. Gynecol. Reprod. Biol. 2018;222:171-175. DOI: 10.1016/j.ejogrb.2018.01.026.
23. Sletten E.T., Arnes M., Lyså L.M. et al. Significance of progesterone receptors (PR-A and PR-B) expression as predictors for relapse after successful therapy of endometrial hyperplasia: a retrospective cohort study. BJOG. 2019;126(7):936-943. DOI: 10.1111/1471-0528.15579.
24. Donchenko D.V., Rahimov V.A., Denisse E.I., Stanojevic U .S. Pathogenetic aspects of precancerous colon: the key to solving the problem of colorectal adenocarcinoma. Vestnik of the Russian Scientific Center of Roentgenoradiology. 2019;19(3):1-18. (In Russ.)
25. van Velzen M.J.M., Derks S., van Grieken N.C.T. et al. MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma. Cancer Treat. Rev. 2020;86:102024. DOI: 10.1016/j.ctrv.2020.102024.
26. Cheng X., Wang X., Nie K. et al. Systematic pancancer analysis identifies TREM2 as an immunological and prognostic biomarker. Front. Immunol. 2021;12:646523. DOI: 10.3389/fimmu.2021.646523.
27. Koroleva E.I., Musaelyan A.A., Nazarov V.D. et al. Molecular markers of endometrial carcinoma and associated clinicopathological features. Molecular Medicine. 2022;20(3):34-40. DOI: 10.29296/24999490-2022-03-06. (In Russ.)
28. Rumyantsev A.A. Efficient sequence of therapy for advance d and metastatic endometrial cancer. Tumors of Female Reproductive System. 2022;18(2):119-126. DOI: 10.17650/1994-4098-2022-18-2-119-126. (In Russ.)
29. Roudko V., Cimen Bozkus C., Greenbaum B. et al. Lynch syndrome and MSI-H cancers: from mechanisms to “off -the-shelf” cancer vaccines. Front. Immunol. 2021;12:757-804. DOI: 10.3389/fimmu.2021.757804.
Review
For citations:
Kazachkov E.L., Zatvornitskaya A.V., Kazachkova E.A., Voropaeva E.E. Microsatellite instability and hyperplastic processes of the uterine mucosa. Journal of Siberian Medical Sciences. 2023;(2):62-76. (In Russ.) https://doi.org/10.31549/2542-1174-2023-7-2-62-76
Views:
150
Email this article 